Literature DB >> 9709306

Kaposi's sarcoma-associated herpesvirus-encoded oncogenes and oncogenesis.

P S Moore1, Y Chang.   

Abstract

Molecular biologic studies of Kaposi's sarcoma-associated herpesvirus (KSHV) have identified a number of potential viral oncogenes that may contribute to KSHV-related neoplasia including a D-type cyclin, an IL-6-like cytokine, and a novel member of the interferon regulatory factor family. KSHV is functionally related to other DNA tumor viruses by encoding specific proteins to inhibit pRb, pro-apoptotic, and interferon-signaling tumor suppressor pathways. The virus appears to employ molecular piracy of cellular regulatory genes as a mechanism to avoid cellular antiviral responses. The transparency of the KSHV genome allows ready identification of the cellular regulatory pathways which may be involved in transformation by KSHV. This provides strong support to the notion that some tumor suppressor pathways serve the dual function of being antiviral pathways to induce cell cycle arrest, apoptosis, and enhanced cell-mediated immunity in response to virus infection. Neoplasia may result from specific viral strategies to overcome these host defense pathways.

Entities:  

Mesh:

Year:  1998        PMID: 9709306     DOI: 10.1093/oxfordjournals.jncimonographs.a024176

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  21 in total

1.  Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells.

Authors:  Shou-Jiang Gao; Jian-Hong Deng; Fu-Chun Zhou
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 2.  Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.

Authors:  Qiliang Cai; Suhbash C Verma; Jie Lu; Erle S Robertson
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

3.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

Review 4.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

5.  Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters.

Authors:  J Jeong; J Papin; D Dittmer
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Cellular corepressor TLE2 inhibits replication-and-transcription- activator-mediated transactivation and lytic reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhiheng He; Yunhua Liu; Deguang Liang; Zhuo Wang; Erle S Robertson; Ke Lan
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

7.  Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein.

Authors:  Melanie M Brinkmann; Mark Glenn; Lucille Rainbow; Arnd Kieser; Cornelia Henke-Gendo; Thomas F Schulz
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Lytic replication-defective Kaposi's sarcoma-associated herpesvirus: potential role in infection and malignant transformation.

Authors:  Jian-Hong Deng; Yan-Jin Zhang; Xin-Ping Wang; Shou-Jiang Gao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 9.  The role of infectious agents in the etiology of ocular adnexal neoplasia.

Authors:  Varun Verma; Defen Shen; Pamela C Sieving; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 6.048

10.  TLR-TRIF pathway enhances the expression of KSHV replication and transcription activator.

Authors:  Florencia Meyer; Erica Ehlers; Andrew Steadman; Thomas Waterbury; Mingxia Cao; Luwen Zhang
Journal:  J Biol Chem       Date:  2013-05-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.